Rice G C, Ling V, Schimke R T
Cancer Biology Research Laboratory, Stanford University, CA 94305.
Proc Natl Acad Sci U S A. 1987 Dec;84(24):9261-4. doi: 10.1073/pnas.84.24.9261.
We have determined the frequency with which Chinese hamster cells become resistant to either methotrexate or doxorubicin (former generic name, adriamycin) alone or to the two drugs simultaneously. We find that the frequency of acquisition of simultaneous resistance is 10-100 times higher than that predicted from the frequency of each resistance selected independently. In approximately 50% of cloned resistant variants, resistance is the result of amplification of the dihydrofolate reductase gene (methotrexate) and/or of the multiple-drug-resistance P-glycoprotein gene (doxorubicin). Prior exposure of cells to hypoxia markedly enhances these resistance frequencies. Our results indicate that the simultaneous emergence of resistance to these two cancer chemotherapeutic agents are not independent events, and we interpret them to constitute two consequences of the same basic process occurring at a high frequency.
我们已经确定了中国仓鼠细胞对甲氨蝶呤或阿霉素(以前的通用名,阿霉素)单独耐药或对这两种药物同时耐药的频率。我们发现,同时获得耐药性的频率比根据单独选择的每种耐药性频率预测的频率高10 - 100倍。在大约50%的克隆耐药变体中,耐药性是二氢叶酸还原酶基因(甲氨蝶呤)和/或多药耐药P - 糖蛋白基因(阿霉素)扩增的结果。细胞预先暴露于低氧环境会显著提高这些耐药频率。我们的结果表明,对这两种癌症化疗药物同时出现耐药性并非独立事件,我们将其解释为同一基本过程以高频率发生的两种结果。